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Abstract 
Bardet-Biedl syndrome is a rare autosomal recessive multi-system disease 
characterised by retinal dystrophy, renal malformation, obesity, intellectual disability, 
polydactyly and hypogonadism.  Nineteen disease causing genes (BBS1-19) have 
been identified of which mutations in BBS1 are most common in North America and 
Europe.  
A hallmark of the disease, renal malformation is heterogeneous and is a cause of 
morbidity and mortality through the development of chronic kidney disease. We 
studied the prevalence and severity of chronic kidney disease in the largest reported 
cohort of patients with Bardet-Biedl syndrome-related renal disease, further 
elucidating the phenotype and identifying risk indicators.  
Thirty six per cent of children and 42% of adults had chronic kidney disease (CKD). 
End stage renal disease (CKD4-5) was present in 8% of adults.  In childhood, CKD 
was primarily detected within the first year of life and end stage renal disease was 
present in 6%. Albuminuria was associated with severe renal disease (estimated 
glomerular filtration rate <45 mls/min/1.73m2). Fifty one percent of patients had 
structural renal abnormalities on ultrasonography and 35% were hypertensive. 
These risk factors also correlated statistically with CKD3b-CKD5.   
Genotype and mutation type were statistically significant risk indicators. Mutations in 
BBS1 or two missense mutations were associated with less severe or lack of chronic 
kidney disease in comparison to mutations in BBS10 or two truncating mutations. 
This study identifies risk factors to be considered in genetic counselling and presents 
paediatric and adult nephrology management schemes for BBS.  
Introduction 
Bardet-Biedl syndrome (BBS) is a rare autosomal recessive ciliopathy characterised 
by rod cone dystrophy, renal malformations, learning difficulties, obesity, post-axial 
polydactyly and hypogonadism.1 Nineteen disease causing genes have been 
identified (BBS1-BBS19) in the last two decades. BBS genes code for proteins that 
localise to the cilia or the basal body and are thought to be involved in cilia 
development and maintenance2. Mutations in BBS genes lead to defective cilia. 
Sequencing of known disease causing genes confirms a clinical diagnosis of BBS in 
around 80% of patients2. Variable expressivity is a hallmark of BBS and both inter- 
and intrafamilial phenotypic variation is observed.2  
Structural renal and urinary tract anomalies and renal dysfunction is a cause of 
considerable morbidity and reported to affect 53-82% of patients with BBS.2-4;4-6 The 
primary renal phenotype is highly variable ranging from cystic tubular disease, 
dysplastic renal disease and focal segmental glomerulosclerosis to concentrating 
defects.3-7 Lower urinary tract dysfunction is observed in many patients and may 
have upper renal tract sequelae.8  It is thought that ciliary dysfunction leads to 
disturbance of the non-canonical Wnt signalling pathway which may contribute to the 
development of cystic kidney disease classically associated with BBS.2 Secondary 
renal disease may occur as a consequence of hypertension and diabetes which are 
frequently observed in this population. 
The high frequency of renal disease in BBS is a cause of great anxiety among 
patients due to the devastating effect this can have on quality of life, morbidity and 
mortality.4-6 This study examines renal disease in the largest reported cohort of BBS 
patients and identifies indicators of disease which are directly relevant to patient 
management and clinical stratification.    
 
Results 
Overview of the BBS population 
Three hundred and fifty patients attended the adult and paediatric national BBS 
clinics in Birmingham and London over a four year period (2010-14).  The patient 
population ranged in age from birth to 60 years old, with a peak frequency in the five 
to nine year old category, and with few older adults (figure 1). 
Diagnosis was based on clinical phenotyping. Molecular confirmation of the 
diagnosis was achieved in 77% (n=265) of patients on sequencing 13 disease 
related genes.  
 The distribution of genotypes is demonstrated in figure 2. For the purpose of 
statistical analysis mutation type was classified according to severity. One hundred 
and sixteen  patients had two missense mutations, 108 had two truncating mutations 
(nonsense or frameshift), 33 had a combination of missense and truncating 
mutations and the remaining eight patients had other mutation combinations such as 
exon deletions and splice site mutations. 
 
Age of onset of renal disease 
We were able to retrospectively obtain the earliest recorded age of onset of CKD 
stage9 in 58 paediatric patients attending the BBS clinic (figure 3).  All paediatric 
patients with end stage renal failure (ESRF; CKD4-5) were diagnosed before the age 
of 5. The majority of patients with any stage of CKD presented before the age of 10. 
Since the peak referral age to the clinic is late childhood, later recorded onset of 
CKD is likely to reflect significant ascertainment bias as patients may have 
asymptomatic renal disease and no previous renal sonography. 
Observations from the national BBS clinics suggest that patients either develop  
ESRF in childhood or maintain normal or near-normal renal function into adulthood. 
Figure 4 demonstrates the age at which ESRF was first identified in children and 
adults and largely supports this finding. All patients with primary renal disease 
developed ESRF by the age of 15 (n=10). Although under-reported, 6% of the adult 
BBS population report urological complications requiring specialist management. 
Urological abnormalities include neuropathic bladder, vesico-ureteric reflux, urinary 
incontinence and bladder outflow obstructions.  
 
Prevalence of chronic renal disease 
Estimated GFR (eGFR) results were available for 194 adults and 145 paediatric 
patients. Seventy per cent of adult patients had at least two eGFR readings. The 
frequency of each stage of CKD in adults and children is demonstrated in figure 5 
where it is  present in 42% and 36% respectively.  
Genotype and mutation type analyses in adults with BBS revealed statistically 
significant correlations with the presence of severe renal disease defined as CKD 
stage 3b to 5 (eGFR<45 ml/min/1.73m2).  Univariable logistical regression analysis 
indicated that mutations in BBS2, BBS10 and BBS12 were more likely to be 
associated with severe renal disease than mutations in BBS1 (p values: 0.02, 
0.0004, 0.03 respectively) (table 1).  Univariable logistical regression analysis of 
mutation type revealed that truncating mutations and truncating/ missense mutations 
were statistically associated with severe renal disease in comparison to two 
missense mutations (p values= 0.0003, 0.02 respectively) (table 1).  Multivariable 
regression analysis including genotype, mutation type, age, hypertension, type 2 
diabetes, and BMI, revealed that mutations in BBS10 are independently associated 
with severe renal failure (p=0.028) (table 2). 
Proportional frequencies of CKD stages 2, 3, 4 and 5 in adults were compared for 
the commonest genotypes BBS1 and BBS10 as outlined in figure 6a.  Patients with 
BBS1 mutations are more likely to be disease free or have early stage CKD. 
Mutations in BBS10 were more frequently represented with increasing stage of CKD. 
Of note, patients attending our clinics with mutations in BBS1 are statistically 
significantly older than those with mutations in BBS10 (p=0.0011). It is unknown why 
this may the case.  
 The effect of mutation type on proportional frequencies of CKD stages 2-5 was also 
assessed. Patients with all genotypes were included and mutation types classified as 
either missense or truncating (nonsense or frameshift mutations) or other mutations. 
Patients with two missense mutations were compared to patients with two truncating 
mutations (figure 6b). Having two missense mutations was associated with a disease 
free state or early stages of CKD.  Patients with two truncating mutations were more 
likely to have ESRF.  
Previous research indicates that the recurring missense mutation M390R in BBS1 
may be hypomorphic.10;11 We assessed this by comparing adult patients who were 
homozygous for M390R to patients with all other genotypes (figure 6c). Only one 
patient homozygous for M390R had progressed beyond stage 3 CKD. The patient 
presented following renal transplant aged 23 to our service and the cause of renal 
failure was unclear although presumed to be a result of BBS.  
We assessed for the presence of micro- and macroalbuminuria analysing urinary 
albumin/creatinine ratios as a proxy for nephron impairment. Urinary albumin/ 
creatinine ratios were available for 139 adult and paediatric patients. Seven (5%) 
had proteinuria (defined as urinary albumin/ creatinine >30 mg/mmol) and 32 (28%) 
had microalbuminuria (defined as urinary albumin/ creatinine >3.5 mg/mmol12). This 
could be matched to an eGFR in 119 patients. There was a statistically significant 
correlation between severe renal disease and urinary albumin/ creatinine ratios (p= 
0.006). The sample size was inadequate for correlation with genotype and mutation 
type.  
 
Presence of structural abnormalities 
One hundred and seventy seven ultrasound reports from the entire cohort were 
available for our assessment. Eighty seven were unremarkable and 90 revealed 
structural defects. Abnormalities were categorised as atrophic/scarring, echogenic or 
loss of corticomedullary differentiation, cystic or dysplastic, other developmental 
abnormality or hydronephrosis as seen in figure 7. Where several abnormalities were 
present the predominant structural defect is reported. On assessing genotype 
correlations (BBS1 versus BBS10) no association with the presence of structural 
abnormality  was identified (p=0.188).  
Correlating the presence of all cause structural abnormality in adults with CKD 
staging revealed a strong correlation with CKD at stage 3b-5 (p=0.039). All patients 
with a reported renal ultrasound scan and severe renal disease had a detectable 
structural abnormality (n=7).  
Ultrasound reports from 39 paediatric patients with known renal structural 
abnormalities who had both antenatal and postnatal sonography failed to identify the 
anatomical aberration prenatally in 14 patients (36%). 
Five paediatric patients had abnormal antenatal renal ultrasound reports and normal 
postnatal sonography. In all cases non-specific echogenicity was reported 
antenatally and no specific structural abnormalities were detected.  
In this cohort 30 patients presented with sonographic evidence of cystic kidney 
disease which is classically associated with BBS. Twenty four of these patients had 
molecular confirmation of BBS. Patients with mutations in BBS1 and BBS10 
accounted for the majority of genotypes represented (42% and 21% respectively).   
 
Hypertension and diabetes 
Thirty five per cent of adult patients (n=67) in this cohort were found to be 
hypertensive. There is a statistically significant correlation between severe renal 
failure and the presence of anti-hypertensive medication (p=0.003) (table 1) although 
it is not clear if this is an independent risk factor or if it is because antihypertensive 
medication is prescribed as a part of the management of CKD.  There was a 
significant association between the presence of hypertension and albuminuria 
(p=0.0009). Although patients with mutations in BBS10 make up only 20% of 
patients with a known mutation they account for 50% (n=3) of those adult patients 
with molecular confirmation of BBS aged under 25 receiving anti-hypertensive 
medication. The most commonly prescribed antihypertensive medications were ACE 
inhibitors (52%) followed by diuretics (21%), calcium channel blockers (15%), beta 
blockers (8%) and angiotensin receptor blockers (3%).   
Fifteen per cent of adult patients (n=28) were on hypoglycaemic medication. There 
was no statistically significant association with CKD (p=0.471).  
 
Discussion 
To our knowledge this is the largest reported study characterising the renal 
phenotype in BBS. The age distribution of our patient population is most likely a 
reflection of a number of factors affecting patient referral. Children are often referred 
to the service following the onset of visual decline which typically occurs towards the 
end of the first decade of life, accounting for the high frequency of children aged five 
to nine years old. Many children presenting in the first year of life are siblings of 
patients known to the service. The clinical service has been in operation since 2010 
and patients over the age of 60 may not have a known diagnosis of BBS as 
familiarity with the syndrome has only increased in the last two decades. The 
variation of genotypes presented in this study reflects the UK BBS population and is 
similar to that observed by others in Europe and North America.13;14 
Our study suggests that the onset of primary renal disease in children predominantly 
occurs in infancy. For many adult patients it was difficult to accurately determine the 
age of onset of renal disease since patients with CKD are managed locally with an 
annual specialist BBS review. A striking observation is the relatively modest 
difference in prevalence of ESRF (CKD4-5) between adults (8%) and children (6%) 
(figure 5). This supports our hypothesis that patients with BBS primarily either 
develop ESRF in childhood or remain entirely or relatively free of severe renal 
disease.  The small proportion of adult onset severe renal disease may relate to co-
morbidities associated with BBS such as urological complications, hypertension, 
obesity and diabetes.  These are potentially modifiable risk factors which should be 
managed appropriately.  
The prevalence of CKD in this cohort is lower than anticipated based on previous 
estimates3. Forty two per cent of adults have CKD stage 2-5 and only 8% of adult 
patients develop CKD3b-5. There appears to be both genotype and mutation type 
correlations with CKD with increased risk of developing CKD3b-5 for those patients 
who have truncating mutations and mutations in BBS10. This is in keeping with  a 
previous study indicating similar findings for cardiovascular risk factors in this 
group.15 Furthermore, only one of the patients in this study with homozygous BBS1 
M390R mutations developed ESRF. BBS1 M390R is the most common mutation 
observed in the BBS population in Europe and Northern America and patients 
homozygous for M390R make up a significant proportion of the patient population 
(45% of the UK population are homozygous or heterozygous for this mutation, own 
unpublished data). This significant subgroup of patients could be counselled 
regarding their lower risk of progressing to ESRF.   
Guidelines for the management of BBS recommend that every patient should have a 
baseline renal ultrasound examination to assess for the presence of any structural 
abnormalities.16  Although some patients who have abnormal renal ultrasound scans 
do not go on to develop CKD there is a statistically significant correlation between 
structural abnormalities and CKD. This study validates the requirement for a baseline 
postnatal renal ultrasound scan following a diagnosis of BBS. Structural abnormality 
should alert clinicians that close monitoring is required to identify any deterioration in 
renal function. Anecdotal reports of structural renal abnormalities present antentally 
and absent on postnatal sonography could not be confirmed in this study.  
One report17 suggests that mutations in BBS10 are associated with antenatal severe 
cystic kidney disease which is incompatible with life. In this study, the prevalence of 
BBS10 mutations among patients presenting with postnatal sonographic evidence of 
cystic kidney disease (21%, n=5) was consistent with that of the overall study 
population (20%).  The authors are not aware of a higher rate of pregnancy losses in 
families with BBS10 mutations. 
It has previously been suggested that proteinuria is consistently absent in BBS –
associated renal disease.18 This study demonstrates the co-existence of proteinuria 
and CKD and the correlation between severe renal disease and albuminuria. 
Hypertension is a common feature of BBS and we have previously reported on the 
high prevalence of antihypertensive medication in this group. Patients with mutations 
in BBS10 are disproportionately represented in the younger age groups compared to 
patients with mutations in BBS1.15  
In summary, this study maps the prevalence of renal disease in BBS and 
characterises the highly variable renal phenotype. We have identified risk indicators 
as well as potentially protective factors for renal disease. Adults who harbour 
missense mutations in BBS1, have no albuminuria and have normal renal ultrasound 
scans in adulthood are less likely to develop ESRF. Patients with truncating 
mutations in BBS10, albuminuria and abnormal renal ultrasound scans are at 
significantly increased risk of ESRF compared to the general BBS population.  
Primary renal disease as consequence of BBS appears to present in early childhood.  
The evidence presented here could have a direct clinical implication for BBS 
patients. The presence or absence of risk factors should be considered when 
counselling patients and may be used to stratify the clinical service. Previous 
recommendations advise that patients should be reviewed by a nephrologist 
annually unless CKD is present in which case closer monitoring is required. Based 
on this study the authors recommend risk factor- dependent tiered adult and 
paediatric nephrology management approaches as outlined in figures 8a and 8b. 
Adults with the lowest risk of renal disease could receive community nephrology 
follow up and low risk children could be seen less frequently in specialist clinics. All 
patients with end stage renal disease require frequent specialist follow up and those 
with identifiable risk factors or early stable renal disease (CKD1-3) warrant annual 
specialist follow up.  A multi-national study could facilitate the development of a 
statistical renal risk calculator for this unique population. 
 
Concise methods 
Patients 
The following renal parameters were ascertained retrospectively for all 350 patients 
attending the national BBS clinics: known history of renal disease, stage of CKD if 
present, any abnormalities noted on renal ultrasound scanning, estimated glomerular 
filtration rate (eGFR), renal function tests and relevant concomitant factors including 
presence of hypertension, diabetes and obesity. All blood and urinary tests were 
completed following a six hour starvation period. The Modification of Diet in Renal 
disease (MDRD) formula was applied to estimate glomerular filtration rate in all 
adults in keeping with its common use for patients with obesity and diabetes in the 
general population19.  Estimated GFR for the paediatric population was calculated 
according the Schwarz-Haycock formula (height (cm) x 31/ creatinine (µmol/l)).  
Adults were categorised as hypertensive if they were on anti-hypertensive 
medication, had a blood pressure greater than 140/90 mmHg or a blood pressure 
greater than 130/80 in combination with albuminuria. Patients were predominantly of 
Caucasian and South East Asian origin and referrals were made primarily from the 
British national patient support group, clinical geneticists and ophthalmologists in the 
United Kingdom.  
 
Mutation analysis 
Mutation analysis was undertaken through the UK national BBS gene panel which 
encompasses 11 BBS genes including BBS1- BB10 and BBS12 as well as two BBS 
associated genes MKS1 and ALMS1.  
 
Statistical analysis 
Genotype-phenotype analysis was targeted to patients with mutations in the two 
most commonly affected genes: BBS1 and BBS10, as well as the less common 
genotypes BBS2 and BBS12 where adequate sample sizes were available.  
Correlation with mutation type was also assessed. Patients with two known 
missense mutations were compared with two known truncating (nonsense or 
frameshift) mutations and a combination of missense/truncating mutations. The 
nonparametric Mann–Whitney U test was performed to assess differences in median 
age for genotypes BBS1 and BBS10. For the purpose of genotype and mutation type 
analysis children were not included since renal failure appears to occur and progress 
primarily in childhood, hence CKD stage was not considered to be stable until 
adulthood.  Multivariable regression analysis was applied to evaluate genotype-
phenotype analysis and assess the effect of confounders on chronic renal disease. 
The relative burden of each risk factor was described in odds ratios. Statistical 
analyses were conducted in R (R Core Team (2013). R: A language and 
environment for statistical computing. R Foundation for Statistical Computing, 
Vienna, Austria. Retrieved from: http://www.R-project.org/). A 5% confidence level 
was considered statistically significant. All tests were two tailed. 
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Figure legends 
Figure 1. Age distribution of patients 
Figure 2. Figure 2. Distribution of genotypes  
Figure 3. Age and CKD stage at which renal disease was first noted in paediatric 
patients with BBS (n=58) 
Figure 4. Age at onset of end stage renal disease (CKD4-5) and primary pathology 
(n=28) 
Figure 5. Distribution of chronic kidney disease stages in adults and children 
Figure 6. a. Percentage distribution of chronic kidney disease stages in adults. 
Mutations in BBS1 versus BBS10; b. Percentage distribution of chronic kidney 
disease stages in adults. Missense mutations versus truncating mutations. c. 
Percentage distribution of chronic kidney disease stages in adults. BBS1 M390R vs 
other known genotypes. Absolute numbers are indicated in each column. 
Figure 7. Prevalence of structural abnormalities detected on sonography 
Figure 8. a. Nephrology management of adult BBS patients. b. Nephrology 
management of paediatric BBS patients. 
 
 
  
 
  
Table 1. Univariable logistical regression analysis of risk factors for severe renal 
disease in adults. (eGFR<45 ml/min/1.73 m2). All statistically significant findings are 
highlighted in bold. 
Risk factors for severe renal disease  
Risk factor Odds 
ratio 
Confidence interval 
2.5%              97.5% 
P value 
Genetic factors     
Genotype     
     BBS1 mutation Reference    
     BBS2 mutation 4.4 1.28 15.19 0.016 
     BBS9 mutation 2.4 0.12 17.74 0.458    
    BBS10 mutation 7.4 2.49 23.32 0.0003 
    BBS12 mutation 5.9 1.08 28.39 0.0278 
Mutation type     
    Two missense mutations Reference    
    Two truncating mutations 11.4 3.9 41.8 3.43e-05  
    Missense/truncating 6.3 1.5 28.6 0.0116  
Diabetes 0.62 0.14 0.99 0.471 
Hypertension 5.43 2.21 14.29 0.003 
BMI 1.04 0.96 1.10 0.321 
Age 1.02 0.99 1.96 0.154 
Urinary protein     
Urinary albumin/creatinine 
ratio 
1.07 1.02 1.20 0.006 
Structural abnormalities     
USS abnormality 1.32 1.02 1.72 0.039 
 
 
 
 
 
Table 2. Multivariable logistical regression analysis of risk factors for severe renal 
disease in adults. (eGFR<45 ml/min/1.73 m2). All statistically significant findings are 
highlighted in bold. 
Risk factors for severe renal disease  
Risk factor Odds 
ratio 
Confidence interval 
2.5%              97.5% 
P value 
Genotype     
     BBS1 mutation Reference    
     BBS2 mutation 9.5 0.22 572.2 0.219 
    BBS10 mutation 189.9 3.73 83960.35 0.028 
Mutation     
   Two missense Reference    
   Two truncating 3.43 0.26 107.22 0.386 
   Missense/ truncating 34.81 0.57 5145.83 0.095 
Diabetes 0.28 0.002 6.51 0.503 
Hypertension 22.04 0.42 8314.86 0.184 
BMI 0.88 0.73 1.08 0.145 
Age 1.05 0.89 1.28 0.537 
Gender 0.61 0.03 9.05 0.721 
 
 
 
 
 
